Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628954 | 0.81 | LMNA (0.55) | MAPTLMNAKMT2ARECQLSMN1; SMN2 | |
| SCHEMBL4629293 | 0.78 | ALDH1A1 (0.47) | MAPTITGB1ITGA4LMNAALDH1A1 | |
| SCHEMBL2850718 | 0.77 | MAPT (0.49) | MAPTLPAR1ITGB1ITGA4CXCL8 | |
| SCHEMBL4628744 | 0.77 | SCN5A (0.53) | MAPTLPAR1LMNAALDH1A1KMT2A | |
| SCHEMBL4628708 | 0.77 | ALDH1A1 (0.48) | MAPTLMNAALDH1A1AKR1C3KMT2A | |
| SCHEMBL6721277 | 0.76 | GRIN2D (0.53) | MAPTLPAR1KMT2ARECQL | |
| SCHEMBL30479702 | 0.76 | GRIN2D (0.53) | MAPTLPAR1KMT2ARECQL | |
| SCHEMBL7855179 | 0.75 | MAPT (0.50) | MAPTLPAR1ITGB1ITGA4CXCL8 | |
| SCHEMBL4628567 | 0.73 | KMT2A (0.53) | MAPTLMNAALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4627560 | 0.72 | LPAR1 (0.50) | MAPTLPAR1LMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | MAPT 705/4885LPAR1 991/4885ITGB1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.